Comparison of KRAS Mutation Status with Clinical Parameters in Colon Adenocarcinoma

KRAS mutations are mutually exclusive with other activating on EGFR pathway. Detection of associated tumorigenesis, predicates the lack same pathway and shows that application targeted therapy approaches which target proteins in EGFR-MAPK ineffective. In this study, frequency colorectal cancer relationship between mutation status clinical features were assessed. detected 47,7% cases included our study. We determined 76% located codon 12, 9% 13, 61 6% 117 or 146. Determination rates association for different populations important planning treatment strategies nationwide. we have demonstrated is accordance literature. there statistically significant correlation grade status.